Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung

Clinical Oncology

Volumn 23, Issue 8, 2011, Pages 561-562

  Carruthers, R ^a   O'Rourke, N ^a   Mohammed, N ^a   Hicks, J ^a   Brisbane, I ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; DYSPNEA; ESOPHAGITIS; FLUID RETENTION; HUMAN; HYPOFRACTIONATED ACCELERATED RADIOTHERAPY; INFECTION; LETHARGY; LETTER; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRACHEOESOPHAGEAL FISTULA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE FRACTIONATION; DYSPNEA; ESOPHAGITIS; FOLLOW-UP STUDIES; HUMANS; LETHARGY; LUNG NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; VINBLASTINE;

EID: 80052295984     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.05.006     Document Type: Letter

References (3)

1. O'Rourke N., MacBeth F. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol 2010, 22:347-355.
2. Faivre Finn C., Le Pechoux C., Pignon J.P., Auperin A. Reply to: is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol 2011, 23:62-66.
3. Koukourakis M., Hlouverakis G., Kosma L., et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996, 34:315-322.